JP Morgan Maintains Overweight on CytomX Therapeutics, Raises Price Target to $12

Benzinga · 2d ago
JP Morgan analyst Anupam Rama maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and raises the price target from $11 to $12.